U.S. markets open in 1 hour 58 minutes

ZIOPHARM Oncology, Inc. (ZIOP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3500+0.1800 (+5.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.1700
Open3.1300
Bid3.1300 x 1800
Ask3.3600 x 1800
Day's Range3.1300 - 3.3500
52 Week Range2.0600 - 5.9500
Volume1,417,048
Avg. Volume2,708,063
Market Cap720.937M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.3810
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
    GlobeNewswire

    Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell

    BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu. The patient’s T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company’s non-viral Sleeping Beauty transposon transposase system and infused two days after gene transfer. “We are excited to be conducting this important trial for this experimental treatment,” said Dr. Jay Zhang, Chief Executive Officer of TriArm Therapeutics. The Company and Eden BioCell will provide updates regarding the experimental treatment and other patient data in the second half of the year at appropriate venue(s), including scientific conferences, publications and / or bespoke events that the Company may convene. About the Trial “Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients with Advanced Lymphoid Malignancies”This is a single center phase I, open-label dose-escalation trial, for patients with relapsed CD19+ leukemias and lymphomas. Up to 24 patients will be enrolled in this trial. The primary endpoint of the trial is to evaluate the safety and tolerability of autologous CD19-specific T cells manufactured using the RPM process. About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program, and a precisely controlled IL-12 gene therapy. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com. About Eden BioCellIn December 2018, Ziopharm and TriArm Therapeutics announced the launch of Eden BioCell to lead clinical development and commercialization of Ziopharm’s RPM Sleeping Beauty-generated CAR-T therapies in Greater China and Korea. About TriArm TherapeuticsTriArm Therapeutics is a cell therapy company with R&D operations in Germany, United States and Asia. The company is dedicated to the treatment of cancer and autoimmune diseases. Investor Relations Contact:Adam D. Levy, Ph.D., MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E: alevy@ziopharm.com Forward-Looking Statements DisclaimerThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the number of patients to be enrolled, and the timing of updates for, Eden BioCell’s CAR-T Phase I trial. Although Ziopharm’s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in Eden BioCell’s operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis; the strength and enforceability of Ziopharm’s intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharm’s Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

  • Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
    GlobeNewswire

    Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting

    Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancersBOSTON and HOUSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting. The poster highlights work evaluating the ability of the non-viral Sleeping Beauty transposon/transposase gene transfer system to re-direct the specificity of T cells towards p53 and KRAS neoantigens and characterizing the resultant engineered TCR-T cell populations for specificity and function. The poster is entitled “Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system.” The work summarized in the poster demonstrates that multiple TCRs with unique specificities targeting recurrent p53 and KRAS substitutions in frequent HLA haplotypes could be stably expressed using Sleeping Beauty transposition to re-direct peripheral blood T cells towards tumor cells. Dr. Raffaele Baffa, MD, PhD, Chief Medical Officer of Ziopharm said, “We are pleased to share this update on our TCR-T directed work with the scientific community. The Company is working tirelessly on our Phase I/II clinical study for our TCR-T Library, and the work presented in this poster provides us with increased confidence in the scientific rationale behind the trial.” The poster will be presented as part of Session PO.IM02.01 - Adoptive Cell Therapy. The abstract for the poster can be found on the AACR website using this link. The poster will be available for conference participants beginning at 8:30am ET on Saturday, April 10, 2021 and will also be posted on the Ziopharm Oncology website in the Investors section, using this link. About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program, and a precisely controlled IL-12 gene therapy. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com. Investor Relations Contact:Adam D. Levy, Ph.D., MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E: alevy@ziopharm.com

  • What Type Of Shareholders Make Up ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Share Registry?
    Simply Wall St.

    What Type Of Shareholders Make Up ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Share Registry?

    If you want to know who really controls ZIOPHARM Oncology, Inc. ( NASDAQ:ZIOP ), then you'll have to look at the makeup...